Pasithea Therapeutics Corp. (KTTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pasithea Therapeutics Corp. on September 16, 2026. The report addresses the imminent expiration of the Company's publicly traded warrants.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a corporate event notification and does not contain financial statements.
Material Changes
The primary material event is the expiration of the Company's warrants (trading symbol: KTTAW) on September 17, 2026. Upon expiration, any unexercised warrants will cease to be exercisable and will hold no further value. Consequently, the warrants will cease trading on The Nasdaq Capital Market, and the Company will file a Form 25 to delist and deregister them. The Company's common stock (KTTA) will continue to trade on Nasdaq.
Guidance, Outlook, and Risks
Management commentary is limited to the procedural details of the warrant expiration and delisting. No forward-looking guidance, operational outlook, or discussion of new risks or contingencies is provided in this filing.
Investor Verification Checklist
- Verify the expiration date of KTTAW warrants is September 17, 2026.
- Confirm that unexercised warrants will become worthless immediately after expiration.
- Ensure the common stock (KTTA) remains listed and trading on The Nasdaq Capital Market.
- Check for the subsequent filing of Form 25 regarding the delisting of the warrants.